Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Entera Bio (ENTX) Shares Outstanding (Weighted Average) (2017 - 2025)

Entera Bio has reported Shares Outstanding (Weighted Average) over the past 9 years, most recently at $46.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 22.68% year-over-year to $46.2 million, compared with a TTM value of $46.2 million through Dec 2025, up 22.68%, and an annual FY2025 reading of $46.2 million, up 22.68% over the prior year.
  • Shares Outstanding (Weighted Average) came in at $46.2 million for Q4 2025, down from $47.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $47.1 million in Q3 2025 to a low of $21.9 million in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $28.8 million (2023), compared with a mean of $33.1 million.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 57.55% in 2021, then grew 0.01% in 2023.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $26.1 million in 2021, then rose by 10.23% to $28.8 million in 2022, then grew by 0.69% to $29.0 million in 2023, then grew by 29.79% to $37.7 million in 2024, then increased by 22.68% to $46.2 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Shares Outstanding (Weighted Average) are $46.2 million (Q4 2025), $47.1 million (Q3 2025), and $45.1 million (Q2 2025).